skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

A proposal from the US FDA would end quarterly publication of PMA and Humanitarian Device Exemption verdicts in the Federal Register. The agency says the practice is inefficient and duplicates online publication.

 

FDA_Proposes_End_To_Quarterly_Reporting


The US Food and Drug Administration would stop publishing recent PMA and Humanitarian Device Exemption (HDE) approvals or denials in the Federal Register at the end of each quarter under a proposed rule issued on 17 December.

The agency says the move will increase efficiency and reduce duplicative announcements.

Approval and denial notices would still be posted to the FDA’s website under the proposal, and the agency would continue to post summaries of safety and effectiveness data (SSED) for PMAs and summaries of safety and probable benefit (SSPB) for HDEs, as well as putting the information on display under the proposal, which was published in the 17 December Federal Register.

“The proposed rule, if finalized, would allow FDA staff to focus on other agency priorities and utilize FDA staff resources more efficiently,” the proposal explains.

The agency estimates that the change could save $8,000 to $13,000 per year, without passing any costs along to industry.

As well as eliminating quarterly publication of PMA and HDE decisions, the proposed rule includes some needed updates to regulatory language . It will direct requests for copies of current PMA approvals and denials documents and copies of SSED to Freedom of Information staff, rather than to the Division of Dockets Management, per current FDA practice. Additionally, it replaces some outdated references to sections of the Food, Drug and Cosmetic Act.

Comments on the proposal are open at Regulations.gov under Docket No. FDA-2019-N-3101-0001 through 2 March 2020.

おすすめのニュース&レポート

;

お問い合わせ&レポートストア

専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

*一部のサービスでは無料トライアルをご利用になれません。

ご質問等ございましたらお気軽にご連絡下さい。

日本(平日:9時~18時)
電話:+81 (0)3 6273 4260
Email:inquiry.jp@informa.com

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。